ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.67
-0.94%
US Tech 100
19,270.40
0.50%
S&P 500
5,469.30
0.39%
US Dollar vs CAD
1.36696
0.06%
Bitcoin
61,407.25
-0.65%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Mithra Pharmaceuticals SA (MITRA)

  7. Mithra Pharmaceuticals SA (MITRA) News

MITRA

Mithra Pharmaceuticals (MITRA)

Mithra Pharmaceuticals SA
Date:
Sort by:
 Showing the most relevant articles for your search:EU:MITRA
DateTimeSourceHeadlineSymbolCompany
05/28/20248:41AMGlobeNewswire Inc.Mithra postpones its annual general meetingEU:MITRAMithra Pharmaceuticals SA
05/03/202410:30AMGlobeNewswire Inc.Mithra enters into exclusive negotiations with Gedeon Richter and secures continued funding in the context of its monetization processEU:MITRAMithra Pharmaceuticals SA
04/29/202412:00AMGlobeNewswire Inc.Mithra updates on offers received in the context of its monetization process and on its Annual Report 2023EU:MITRAMithra Pharmaceuticals SA
04/22/202412:00AMGlobeNewswire Inc.Mithra secures court protection measures to advance monetization processEU:MITRAMithra Pharmaceuticals SA
03/08/202412:00AMGlobeNewswire Inc.Mithra reports full year 2023 financial resultsEU:MITRAMithra Pharmaceuticals SA
03/05/202412:01AMGlobeNewswire Inc.Mithra announces changes to its executive managementEU:MITRAMithra Pharmaceuticals SA
03/05/202412:00AMGlobeNewswire Inc.Mithra initiates monetization process, receives bridge loan from existing lendersEU:MITRAMithra Pharmaceuticals SA
02/29/20244:42AMGlobeNewswire Inc.DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phaseEU:MITRAMithra Pharmaceuticals SA
02/15/202411:23AMGlobeNewswire Inc.Mithra sells shares in Mayne PharmaEU:MITRAMithra Pharmaceuticals SA
02/06/202412:00AMGlobeNewswire Inc.Mithra updates on cash positionEU:MITRAMithra Pharmaceuticals SA
02/06/202412:00AMGlobeNewswire Inc.Mithra updates on cash positionEU:MITRAMithra Pharmaceuticals SA
12/21/202310:45AMGlobeNewswire Inc.Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in IsraelEU:MITRAMithra Pharmaceuticals SA
12/21/202310:45AMGlobeNewswire Inc.Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in IsraelEU:MITRAMithra Pharmaceuticals SA
12/20/202310:45AMGlobeNewswire Inc.Mithra Completes Pediatric Study of ESTELLE® in Adolescent PatientsEU:MITRAMithra Pharmaceuticals SA
12/20/202310:45AMGlobeNewswire Inc.Mithra Completes Pediatric Study of ESTELLE® in Adolescent PatientsEU:MITRAMithra Pharmaceuticals SA
12/18/202312:00AMGlobeNewswire Inc.Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 TrialEU:MITRAMithra Pharmaceuticals SA
12/18/202312:00AMGlobeNewswire Inc.Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 TrialEU:MITRAMithra Pharmaceuticals SA
12/04/202312:00AMGlobeNewswire Inc.Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in ChinaEU:MITRAMithra Pharmaceuticals SA
11/30/202312:00AMGlobeNewswire Inc.Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United StatesEU:MITRAMithra Pharmaceuticals SA
11/28/202310:45AMGlobeNewswire Inc.Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in AmsterdamEU:MITRAMithra Pharmaceuticals SA
11/07/202312:00AMGlobeNewswire Inc.Mithra’s NEXTSTELLIS® granted additional patent in the United StatesEU:MITRAMithra Pharmaceuticals SA
11/07/202312:00AMGlobeNewswire Inc.Mithra’s NEXTSTELLIS® granted additional patent in the United StatesEU:MITRAMithra Pharmaceuticals SA
11/06/202311:52AMGlobeNewswire Inc.Mithra releases invitation to its extraordinary securities holders’ meetingEU:MITRAMithra Pharmaceuticals SA
10/26/202312:00AMGlobeNewswire Inc.Mithra and Searchlight Pharma sign DONESTA® licensing agreement for CanadaEU:MITRAMithra Pharmaceuticals SA
10/23/202312:00AMGlobeNewswire Inc.Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreementEU:MITRAMithra Pharmaceuticals SA
10/23/202312:00AMGlobeNewswire Inc.Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreementEU:MITRAMithra Pharmaceuticals SA
10/17/202312:00AMGlobeNewswire Inc.Mithra’s Board of Directors to propose the removal of its request for change of the remuneration policy at the Special General MeetingEU:MITRAMithra Pharmaceuticals SA
10/11/202312:15AMGlobeNewswire Inc.Shareholder LetterEU:MITRAMithra Pharmaceuticals SA
10/11/202312:00AMGlobeNewswire Inc.Mithra announces update to the agenda of its upcoming special general shareholders’ meetingEU:MITRAMithra Pharmaceuticals SA
10/10/202311:00AMGlobeNewswire Inc.Mithra to Hold Presentations on Key Role of Estrogens in Women’s Health, Including Estetrol (E4), at FIGO World CongressEU:MITRAMithra Pharmaceuticals SA
 Showing the most relevant articles for your search:EU:MITRA

Your Recent History

EU
NRO
Neurones
LSE
SZ11
Citi Fun 32
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved